Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Allovir Inc ALVR

Healthcare Biotechnology
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life... see more

Recent & Breaking News (NDAQ:ALVR)

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Newsfile February 20, 2024

Levi & Korsinsky Reminds AlloVir Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024 - ALVR

Accesswire February 20, 2024

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of AlloVir, Inc. (ALVR) Shareholders

Accesswire February 20, 2024

Class Action Filed Against AlloVir, Inc. (ALVR) Seeking Recovery for Investors - Contact Levi & Korsinsky

PR Newswire February 20, 2024

AlloVir, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ALVR

Accesswire February 20, 2024

Levi & Korsinsky Notifies Shareholders of AlloVir, Inc.(ALVR) of a Class Action Lawsuit and an Upcoming Deadline

Accesswire February 20, 2024

ALVR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds AlloVir Inc. Investors to Join the Class Action Lawsuit!

Accesswire February 20, 2024

ROSEN, NATIONAL TRIAL LAWYERS, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALVR

Newsfile February 19, 2024

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Newsfile February 19, 2024

AlloVir, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights - ALVR

Accesswire February 19, 2024

Levi & Korsinsky Reminds AlloVir Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024 - ALVR

Accesswire February 19, 2024

ALVR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds AlloVir Inc. Investors to Join the Class Action Lawsuit!

Accesswire February 19, 2024

AlloVir Deadline Reminder

Newsfile February 18, 2024

Levi & Korsinsky Notifies Shareholders of AlloVir, Inc.(ALVR) of a Class Action Lawsuit and an Upcoming Deadline

Accesswire February 18, 2024

ALVR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds AlloVir Inc. Investors to Join the Class Action Lawsuit!

Accesswire February 18, 2024

Lost Money on AlloVir, Inc.(ALVR)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

Accesswire February 17, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AlloVir, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALVR

Newsfile February 17, 2024

ROSEN, SKILLED INVESTOR COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALVR

PR Newswire February 16, 2024

AlloVir, Inc. Class Action: Levi & Korsinsky Reminds AlloVir Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024 - ALVR

Accesswire February 16, 2024

ALLOVIR SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options

PR Newswire February 16, 2024